Apogee Therapeutics (APGE) Short-term Investments (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Short-term Investments data on file, last reported at $608.1 million in Q1 2026.

• Quarterly Short-term Investments rose 49.63% year-over-year to $608.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $608.1 million (up 49.63% YoY) and the FY2025 annual result came in at $598.6 million, up 58.01% from the prior year.
• Short-term Investments advanced to $608.1 million in Q1 2026 per APGE's latest filing, from $598.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $608.1 million in Q1 2026 and bottomed at $234.6 million in Q3 2023.
• The 4-year median for Short-term Investments is $381.2 million (2025), against an average of $401.0 million.
• The widest annual swing landed in 2024, when Short-term Investments soared 73.6%; it then gained 2.97% in 2025.
• Tracing APGE's Short-term Investments over 4 years: stood at $277.1 million in 2023, then jumped by 36.7% to $378.9 million in 2024, then surged by 58.01% to $598.6 million in 2025, then increased by 1.58% to $608.1 million in 2026.
• Per Business Quant, the three latest APGE Short-term Investments figures stand at $608.1 million (Q1 2026), $598.6 million (Q4 2025), and $419.4 million (Q3 2025).

Peer Comparison